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This manuscript describes the 6 year evolution of our center’s research into ovarian
functions of the FMR1 gene, which led to the identiﬁcation of a new normal CGGn
range of 26–34. This “new” normal range, in turn, led to deﬁnitions of different alleles
(haplotypes) based on whether no, one or both alleles are within range. Speciﬁc alleles
then were demonstrated to represent distinct ovarian aging patterns, suggesting an
important FMR1 function in follicle recruitment and ovarian depletion of follicles. So
called low alleles, characterized by CGGn<26, appear associated with most signiﬁcant
negative effects on reproductive success.Those include occult primary ovarian insufﬁciency
(OPOI), characterized by prematurely elevated follicle stimulating hormone (FSH) and
prematurely low anti-Müllerian hormone, and signiﬁcantly reduced clinical pregnancy rates
in association with in vitro fertilization (IVF) in comparison to women with normal (norm)
and high (CGGn>34) alleles. Because low FMR1 alleles present in approximately 25% of all
females, FMR1 testing at young ages may offer an opportunity for earlier diagnosis of OPOI
than current practice allows. Earlier diagnosis of OPOI, in turn, would give young women
the options of reassessing their reproductive schedules and/or pursue fertility preservation
via oocyte cryopreservation when most effective.
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It has been known for decades that premutation range mutations
of the fragileXmental retardation (FMR1) gene (CGGn55−200) are
associated with greatly increased female risk of primary ovarian
insufﬁciency (POI;Wittenberger et al., 2007). Neither endocrinol-
ogists nor geneticists, however, considered the possibility that the
gene, beyond widely investigated neuro-psychiatric effects, giv-
ing it the name “fragile X chromosome,” may also have a role in
ovarian function.
This idea arose at our center in 2008, and was immedi-
ately encouraged when we demonstrated that CGGn appeared
in infertile women associated with follicle stimulating hormone
(FSH) and anti-Müllerian hormone (AMH), both parameters
of functional ovarian reserve (FOR; Gleicher et al., 2009a).
Moreover, women with autoimmune-associated occult POI
(OPOI, also called premature ovarian aging, POA) demon-
strated signiﬁcantly lower CGGn (in the new “normal” range)
than non-autoimmune women with OPOI who, therefore,
were presumed to have FMR1-related OPOI (Gleicher et al.,
2009b).
The hypothesis of an FMR1-associated ovarian function effect
was further supported when a literature review revealed a 1991
article by Fu et al. (1991) which, as a side note, in the gen-
eral population reported a very prominent distribution peak at
CGGn30−31 (Figure 1). It to us appeared “destined” to represent
an additional function of the FMR1 gene within what then was
considered the normal range of CGGn. Seeing this spiking dis-
tribution peak in an otherwise spread-out distribution pattern,
we suspected it to represent the gene’s hitherto unknown ovarian
function.
We subsequently found a 2003 manuscript by Chen et al.
(2003) reporting CGGn30 as the switching point between posi-
tive and negative message and maximal translation for the gene,
which only further strengthened our conviction that we, likely,
indeed had discovered a new ovarian function of the FMR1 gene.
It, however, remained to be determined what exactly this function
entailed.
DEFINING THE OVARIAN FUNCTION OF THE FMR1 GENE
We then in a series of papers attempted to deﬁne how the FMR1
gene affects ovarian function. First, we established the “normal”
CGGn range for this presumed ovarian function of the gene at
26–34 (Gleicher et al., 2010c,d), a range that not only included at
midpoint above noted switching point between positive and neg-
ative message at CGGn30 (Chen et al., 2003) but also the large
distribution peak at CGGn29−30, reported by Fu et al. (1991;
Figure 1).
Establishing a new “normal” range allowed for deﬁnition of
new alleles (haplotypes) for the gene, which, of course, were
distinctively different from the traditional CGGn mutations [nor-
mal, intermediate (“gray zone”), premutation and full mutation],
used to deﬁne neuro-psychiatric risks, including the fragile X
syndrome (Wittenberger et al., 2007). These new alleles (haplo-
types) were also called genotypes, and were deﬁned as normal
(norm) if both alleles were in normal range, as heterozygous
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FIGURE 1 | Distribution of CGGn in general population. Modiﬁed with
permission from Fu et al. (1991).
(het) if one allele was outside normal range and as homozygous
(hom) if both alleles were outside normal range (Gleicher et al.,
2010c,d).
Up to that point, the genetic literature, almost exclusively,
had only concentrated on the expansive properties of the FMR1
gene into abnormally high CGGn ranges. They were associ-
ated with well known neuro-psychiatric conditions at premu-
tation (CGGn∼55−200) and full mutation range CGGn expan-
sions (CGGn>200). Our center’s research, therefore, initially
also concentrated only on expanding CGGn to the right of the
by Fu et al. (1991) reported population peak at CGGn29−30
(Gleicher et al., 2009c,d). Because of the rather symmetrical dis-
tribution pattern of CGGn on both sides of the distribution
peak (Figure 1), we, however, also initiated investigations of
low alleles (CGGn<26), once we discovered that the risk for
OPOI on both sides of the CGGn distribution peak was similar
(Gleicher et al., 2009e).
As further discussed below, we quickly learned that low CGGn
counts, indeed, appear associatedwith someof themost important
effects of the FMR1 gene on female reproduction. We, therefore,
started subdividing above described “new” haplotypes (geno-
types) into so-called sub-genotypes or low (CGGn< 26) and high
(CGGn>34) alleles (Gleicher et al., 2010c,d).
Assessing young oocyte donors and infertile women at dif-
ferent ages, using these newly deﬁned FMR1 alleles, ovarian
functions of the gene came into clearer view: different FMR1
alleles were found associated with fairly typical ovarian aging
patterns. Women with norm genotypes based on AMH levels
followed a more or less normal ovarian aging pattern. Het-low
carriers, in contrast, lost FOR at an accelerated pace, while carri-
ers of het-high alleles throughout life appeared to recruit slower
than other haplotypes and, therefore, at advanced ages present
with best FOR (Gleicher and Barad, 2010; Gleicher et al., 2010c,
2012b,c).
Because hom patients are rare, especially when sub-divided into
sub-genotypes, functions of homhaplotypes are not aswell deﬁned
as norm and het patients. Preliminary, and mostly yet unpub-
lished observations of hom populations suggest typical accelerated
behavior if both alleles are either high or low but high/low hom
patients appear to differ very signiﬁcantly in ovarian pheno-
type, likely based on which allele is inactivated (Gleicher et al.,
unpublished data).
Based on these clinical observations we, therefore, concluded
that the FMR1 gene, likely, is involved in follicle recruitment,
though in which way still, remains to be determined.
Additional observations added to the picture: while the normal
range of CGGn26−34 is the same among all races, the distribution
of individual alleles varies between races, with women of African
descent demonstrating disproportionally more low and fewer high
alleles, while Asian women (most were Chinese Han) demon-
strate disproportionally more high FMR1 and very few low alleles.
Caucasians (including Hispanics), most diverse in FMR1 allele
distribution, fell in between the other two racial groups (Gleicher
et al., 2010b, 2012a).
An increased prevalence of low alleles in women of African
descent may, at least in part, contribute to their lower IVF preg-
nancy rates in comparison to Caucasian women, widely reported
in the IVF literature (Gleicher et al., 2011). Women with low
FMR1 alleles, adjusted for covariates such as age, demonstrate
signiﬁcantly lower IVF pregnancy rates than women with norm
genotypes (Gleicher et al., 2010d, 2011), an observation recently
again conﬁrmed in a greatly expanded study (Kushnir et al., 2014).
Though clinically often difﬁcult to recognize, differences in
ovarian aging patterns based on FMR1 mutations can already
be observed in young oocyte donors (Gleicher et al., 2013a) and,
therefore, can also be utilized to optimize egg donor selection
(Gleicher et al., 2010a). A 4 year follow up of young, carefully
selected egg donors recently demonstrated that donors carrying
low FMR1 alleles already at their young ages signiﬁcantly deviated
from donors with norm and high alleles in FOR, as assessed by
AMH levels (Kushnir et al., unpublished data).
Trying to better understand underlying physiological mecha-
nisms for the observed IVF outcome differences between FMR1
alleles, we discovered that women with low alleles convert dehy-
droepiandrosterone (DHEA) to testosterone (T) poorer thanother
mutations (Weghofer et al., 2012). Since LFOR is associated with
low T levels (Gleicher et al., 2013b) and the increase in T after
DHEA supplementation is predictive of pregnancy success in IVF
(Gleicher et al., 2013c), this observation, at least partially, may
explain lower IVF pregnancy rates in association with low FMR1
alleles.
In over 5 years we, thus, succeeded in describing a well deﬁned
new function of the FMR1 gene, which affects the ovarian aging
process, reﬂected in FOR levels at different ages. Key studies by
other investigators are brieﬂy summarized below.
CONCOMITANT OBSERVATIONS IN OTHER LABORATORIES
In a mouse model that carries a human FMR1 premutation
allele, Lu et al. (2012) reported that FMR1 premutation RNA
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reduces the number of growing follicles in ovaries, and, thereby,
impairs female fertility, possibly acting through the Akt/mTOR
pathway. In another mouse model, a FX-PM mouse with 130
CGG repeats, Hoffman et al. (2012) demonstrated normal ovar-
ian development and establishment of a normal primordial follicle
pool. The animals, however, demonstrated much faster folli-
cle loss, in concordance with what could be interpreted as the
equivalent of OPOI (Hoffman et al., 2012). In an even more
recent paper, Ascano et al. (2012) reported that a Fmr1−/−
mouse model showed unexpected signs of premature follicular
over-development. All of these animal studies, therefore, offer
supporting evidence for a signiﬁcant role of the FMR1 gene in
ovarian physiology.
Ferder et al. (2013) demonstrated in a rat model the expression
of fragile X mental retardation protein (FMRP) in granu-
losa, theca and germ cells at all stages of follicle develop-
ment. Moreover, these authors also demonstrated changes in
Fmr1 expression at protein as well as mRNA levels. Speciﬁcally,
FMRP expression increased with advancing follicle development,
with preantral and early antral follicles demonstrating similar
Fmr1 transcript, and decreased expression in preovulatory tran-
scripts. The authors detected four different isoforms of FMRP
during different stages of follicle maturation, with expression
patterns varying from what they observed in brain and testis
(Ferder et al., 2013).
Demonstration of similarly broad presence of FMR1 at mRNA
and protein levels in the human ovary would resolve further ques-
tions about the importance of this gene for ovarian physiology.
Our center is currently conducting studies to further elucidate
the relevance of FMR1 mRNA and FMRP in different clinical
situations affecting ovarian function.
Published clinical data from outside our laboratory have so far
not included information on low CGGn alleles and, therefore,
appear limited in scope and clinical relevance. Some, how-
ever, do offer interesting information: Schuettler et al. (2011),
who assessed DNA and RNA samples from 74 women with
idiopathic POI in order to evaluate the quantitative expres-
sion of FMR1 in peripheral leukocytes and in relation to their
CGGn is one example. Only women with POI demonstrated
a large variance in FMR1 transcript from leukocyte RNA sam-
ples, but this variance did not correlate to CGGn. They con-
cluded that all women with CGGn<26 and/or CGGn>34, in
other words with CGGn outside of the new “normal” range for
ovarian function we had described, appear to experience what
they called “relaxed” transcription control. As a consequence,
they, therefore, are at risk for OPOI (i.e., premature ovarian
aging).
Pastore et al. (2012) reported that women with LFOR
present with overrepresentation of CGGn35−44 alleles, which
in our mutation classiﬁcation would mostly correspond to high
FMR1 alleles (Gleicher et al., 2010c,d). Similarly, Barasoain
et al. (2013) reported in a Basque population with FSH lev-
els above 10.0 mIU/mL, using traditional mutation designations
for neuro-psychiatric risks, an increased prevalence of interme-
diate and premutation range alleles. These authors, therefore,
also only commented on what we would describe as high allele
patients.
But not all reported studied were able to demonstrate differ-
ences in CGGn between fertile and infertile women. De Geyter
et al. (2014) were unable to demonstrate “expanded” CGGn in
infertile women and Voorhuis et al. (2013), in our opinion incor-
rectly, dismissed a role for the FMR1 gene in the ovarian aging
process because CGGn was in their study not predictive of age at
menopause.
While we never speciﬁcally investigated in our studies whether
the FMR1 gene affects age of menopause, we also noted that FOR
curves for all the differentFMR1 alleles unite at advanced ages, sug-
gesting a commonmenopause age for all of the haplotypes we have
described. Different haplotypes, however, “take different roads” to
that meeting point (Gleicher et al., unpublished data). We, there-
fore, do not agree with the conclusions reached by Voorhuis et al.
(2013).
Furthermore, some reports do suggest a possible FMR1
effect on menopause age: Sullivan et al. (2005) and Ennis et al.
(2006) suggest such an effect likely around CGGn<80, a mid-
range expansion size within the premutation range, concluding
that menopause age is associated in a non-linear way with
CGGn.
THE FUTURE
Elucidating the function of FMR1 mRNA and FMRP at different
stages of folliclematuration appears of primary importance. Based
on above described clinical observation we, indeed, would suspect
that both may differ in association with different FMR1 alleles
(genotypes and sub-genotypes).
The FMR1 gene may, however, also acquire additional signif-
icance as a prognostic diagnostic tool: we above noted that our
data in young oocyte donors suggest that FOR in young women
with low FMR1 mutations already at very young ages declines
signiﬁcantly more rapidly than in women with either norm or
hom alleles. Since approximately a quarter of all women carry a
low FMR1 allele (Gleicher et al., 2010c,d), this observation would
suggest that approximately one quarter of the female popula-
tion can be deﬁned as “at risk” for LFOR at prematurely young
ages.
If conﬁrmed, assessments of FMR1 mutations at young ages,
possibly in association with other risk factors, could identify a high
risk sub-population of young women, who, with careful longitu-
dinal assessments of FOR, can be diagnosed at much younger ages
than current practice allows for. Such early diagnosis of LFOR
would then allow women to either enhance their reproductive
timing or pursue fertility preservation at still young ages, when
fertility preservation is most effective.
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